News

Filter

Current filters:

Rare diseasesEisai

UPDATE: FDA approves Eisai’s Lenvima for a type of thyroid cancer and expands use of Banzel

UPDATE: FDA approves Eisai’s Lenvima for a type of thyroid cancer and expands use of Banzel

14-02-2015

The US Food and Drug Administration on Friday granted approval for Japanese pharma major Eisai’s Lenvima…

BanzelEisailenvatinibLenvimaNeurologicalOncologyPharmaceuticalRare diseasesRegulationUSA

Eisai’s amatuximab gains orphan status in EU for malignant mesothelioma

Eisai’s amatuximab gains orphan status in EU for malignant mesothelioma

22-01-2014

The investigational monoclonal antibody amatuximab (development code: MORAb-009), has today been granted…

amatuximabEisaiEuropePharmaceuticalRare diseasesRegulation

Eisai's new Belgium operation to help firm's globalization aims

16-09-2013

Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania), a division of Japanese drug major Eisai…

EisaiEuropeHalavenInovelonMarkets & MarketingOncologyPharmaceuticalRare diseases

EU approval for Eisai's epilepsy drug Fycompa and Vertex' Kalydeco

30-07-2012

Japanese drug major Eisai (TYO: 4523) says that the European Commission has approved for marketing its…

EisaiEuropeFycompaKalydecoNeurologicalPharmaceuticalRare diseasesRegulationVertex

COMPANY SPOTLIGHT

Menarini

Back to top